Early initiation of guideline-directed medical therapy in patients with cardiogenic shock supported with Impella(®): a two-center retrospective study

对接受 Impella® 支持的心源性休克患者尽早启动指南指导的药物治疗:一项双中心回顾性研究

阅读:1

Abstract

BACKGROUND: Determining the optimal timing for initiating guideline-directed medical therapy (GDMT) in survivors of cardiogenic shock remains a clinical challenge. Clinicians must balance the urgency of early intervention to prevent adverse remodeling with the risk of hemodynamic instability. This study tested the hypothesis that initiating GDMT early during the intensive care unit (ICU) stay is associated with improved 6-month clinical outcomes in this high-risk population. METHODS: In a retrospective, two-center study of 42 survivors of Impella(®)-supported cardiogenic shock, patients were stratified by their simple GDMT score at ICU discharge (high-score group: score ≥ 4, n = 24 vs. low-score group: score < 4, n = 18). The primary endpoint was a 6-month composite of all-cause mortality and heart failure readmission. RESULTS: The high-score group demonstrated significantly superior 6-month event-free survival compared to the low-score group (log-rank p < 0.001). Additionally, this group achieved higher GDMT scores at hospital discharge (median: 8.0 vs. 2.0, p < 0.001), with a greater proportion achieving a score ≥ 5 (83.3% vs. 27.8%, p < 0.001). CONCLUSION: Our findings suggest that early initiation of GDMT during ICU stabilization is associated with improved 6-month outcomes in survivors of cardiogenic shock. This hypothesis-generating study provides a rationale for future prospective trials to validate this goal-directed strategy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。